Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Verseon Corp    VSN

VERSEON CORP (VSN)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsCalendarCompany 
OFFRE
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
09/18/2018 09/19/2018 09/20/2018 09/21/2018 09/24/2018 Date
139.5(c) 138.5(c) 138.5(c) 138.5(c) 138.5 Last
0 0 0 1 500 0 Volume
0.00% -0.72% 0.00% 0.00% 0.00% Change
More quotes
Company
Verseon Corp. engages in the development and design of pharmaceutical products.It focuses on drug discovery technology to seed a growing portfolio of programs targeting diverse disease areas, currently consisting of anticoagulation, diabetic macular edema, hereditary angioedema, and oncology.The... 
More about the company
Latest news on VERSEON CORP
09/20VERSEON : lsquo;s New Blockchain Technology Aims To Transform Global Investment ..
AQ
09/18VERSEON : Unveils New Blockchain Technology
BU
09/13VERSEON : Commences Phase I Trial for Precision Oral Anticoagulant VE-1902
BU
08/23VERSEON : Interim Report Charts Progress of Development Programs as It Submits P..
AQ
08/16VERSEON : Research Conducted by M. Sivaraja and Co-Researchers Has Updated Our K..
AQ
08/14VERSEON : Interim Report Charts Progress of Development Programs as It Submits P..
BU
06/21VERSEON : to Initiate Phase I Study to Evaluate a New Precision Oral Anticoagula..
AQ
06/21VERSEON : Presents New Data on its Precision Oral Anticoagulants at BIO Internat..
AQ
06/14VERSEON : to Initiate Phase I Study to Evaluate a New Precision Oral Anticoagula..
BU
06/11VERSEON : Presents New Data on its Precision Oral Anticoagulants at BIO Internat..
BU
More news
Sector news : Biotechnology & Medical Research - NEC
09/19NOVARTIS : U.K. Pulls Brakes on Novartis' CAR-T Drug in First European Setback -..
DJ
09/19NOVARTIS : U.K. Pulls Brakes on Novartis' CAR-T Drug for Some Patients Despite D..
DJ
09/19GILEAD SCIENCES : UK rejects adult Novartis CAR-T therapy, after 'yes' in kids
RE
09/18REGENERON PHARMACEUTICALS : Sanofi pledges to keep up its restructuring efforts
RE
09/14Allogene, Which Announced Pfizer Agreement in April, Discloses IPO Plans
DJ
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
09/18Verseon Unveils New Blockchain Technology  
09/18Drug Discovery Platform Verseon Launches Blockchain-Based Securities Exchange.. 
09/18$BLOCK Verseon launches ‘transformative blockchain technology’ for funding dr.. 
09/18Are they really doing this?????? Verseon Corporation $VSN unveils new blockc.. 
09/13Verseon gets approval for VE-1902 clinical trial  
More tweets
Qtime:3
Chart VERSEON CORP
Duration : Period :
Verseon Corp Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VERSEON CORP
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Managers
NameTitle
Adityo Prakash Chief Executive Officer & Executive Director
Thomas Arnold Hecht Non-Executive Chairman
Eniko Fodor Chief Operating & Financial Officer
David Kita Vice President-Research & Development
Grover T. Wickersham Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
VERSEON CORP13.99%272
CELLTRION, INC.--.--%33 388
IQVIA HOLDINGS INC30.32%25 763
LONZA GROUP18.80%24 291
INCYTE CORPORATION-29.69%14 156
SEATTLE GENETICS, INC.45.35%12 348